The development of anticyclic citrullinated peptide (anti‐CCP) antibody following severe COVID‐19
Objectives The dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID‐19). This study was conducted to clarify the occurrence of autoantibodies (AABs) associated with systemic autoimmune rheumatic diseases (SARDs) in hospitalized patients with a modera...
Saved in:
Published in | Immunity, Inflammation and Disease Vol. 12; no. 5; pp. e1276 - n/a |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
John Wiley & Sons, Inc
01.05.2024
John Wiley and Sons Inc Wiley |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Objectives
The dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID‐19). This study was conducted to clarify the occurrence of autoantibodies (AABs) associated with systemic autoimmune rheumatic diseases (SARDs) in hospitalized patients with a moderate, severe, and critical form of COVID‐19.
Methods
The serum samples obtained from 176 hospitalized COVID‐19 patients were investigated in this study, including patients with moderate (N = 90), severe (N = 50), and critical (N = 36) forms of COVID‐19. Also, the serum samples collected from healthy subjects before the COVID‐19 pandemic were used as controls (N = 176). The antinuclear antibodies (ANAs), antidouble‐stranded DNA (anti‐dsDNA), cytoplasmic‐anti neutrophil cytoplasmic antibody (c‐ANCA), perinuclear ANCA (p‐ANCA), antiphospholipid antibodies (aPLs), and anticyclic citrullinated peptide (anti‐CCP) occurrence was evaluated using a solid‐phase enzyme‐linked immunosorbent assay (ELISA).
Results
The results showed that the occurrence of ANAs, anti‐dsDNA, anti‐CCP, c‐ANCA, and p‐ANCA was significantly higher in the COVID‐19 patients compared to serum obtained from healthy subjects (p < .0001, p < .0001, p < .0001, p < .05, and p < .001, respectively). The positive number of anti‐CCP tests increased significantly in severe COVID‐19 compared to the moderate group (p < .01).
Conclusion
Our study further supports the development of autoantibodies related to systemic autoimmune rheumatologic diseases. To the best of our knowledge, this is the first study with a large sample size that reported the occurrence of anti‐CCP in a severe form of COVID‐19. |
---|---|
AbstractList | The dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID-19). This study was conducted to clarify the occurrence of autoantibodies (AABs) associated with systemic autoimmune rheumatic diseases (SARDs) in hospitalized patients with a moderate, severe, and critical form of COVID-19.
The serum samples obtained from 176 hospitalized COVID-19 patients were investigated in this study, including patients with moderate (N = 90), severe (N = 50), and critical (N = 36) forms of COVID-19. Also, the serum samples collected from healthy subjects before the COVID-19 pandemic were used as controls (N = 176). The antinuclear antibodies (ANAs), antidouble-stranded DNA (anti-dsDNA), cytoplasmic-anti neutrophil cytoplasmic antibody (c-ANCA), perinuclear ANCA (p-ANCA), antiphospholipid antibodies (aPLs), and anticyclic citrullinated peptide (anti-CCP) occurrence was evaluated using a solid-phase enzyme-linked immunosorbent assay (ELISA).
The results showed that the occurrence of ANAs, anti-dsDNA, anti-CCP, c-ANCA, and p-ANCA was significantly higher in the COVID-19 patients compared to serum obtained from healthy subjects (p < .0001, p < .0001, p < .0001, p < .05, and p < .001, respectively). The positive number of anti-CCP tests increased significantly in severe COVID-19 compared to the moderate group (p < .01).
Our study further supports the development of autoantibodies related to systemic autoimmune rheumatologic diseases. To the best of our knowledge, this is the first study with a large sample size that reported the occurrence of anti-CCP in a severe form of COVID-19. ObjectivesThe dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID-19). This study was conducted to clarify the occurrence of autoantibodies (AABs) associated with systemic autoimmune rheumatic diseases (SARDs) in hospitalized patients with a moderate, severe, and critical form of COVID-19.MethodsThe serum samples obtained from 176 hospitalized COVID-19 patients were investigated in this study, including patients with moderate (N = 90), severe (N = 50), and critical (N = 36) forms of COVID-19. Also, the serum samples collected from healthy subjects before the COVID-19 pandemic were used as controls (N = 176). The antinuclear antibodies (ANAs), antidouble-stranded DNA (anti-dsDNA), cytoplasmic-anti neutrophil cytoplasmic antibody (c-ANCA), perinuclear ANCA (p-ANCA), antiphospholipid antibodies (aPLs), and anticyclic citrullinated peptide (anti-CCP) occurrence was evaluated using a solid-phase enzyme-linked immunosorbent assay (ELISA).ResultsThe results showed that the occurrence of ANAs, anti-dsDNA, anti-CCP, c-ANCA, and p-ANCA was significantly higher in the COVID-19 patients compared to serum obtained from healthy subjects (p < .0001, p < .0001, p < .0001, p < .05, and p < .001, respectively). The positive number of anti-CCP tests increased significantly in severe COVID-19 compared to the moderate group (p < .01).ConclusionOur study further supports the development of autoantibodies related to systemic autoimmune rheumatologic diseases. To the best of our knowledge, this is the first study with a large sample size that reported the occurrence of anti-CCP in a severe form of COVID-19. Abstract Objectives The dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID‐19). This study was conducted to clarify the occurrence of autoantibodies (AABs) associated with systemic autoimmune rheumatic diseases (SARDs) in hospitalized patients with a moderate, severe, and critical form of COVID‐19. Methods The serum samples obtained from 176 hospitalized COVID‐19 patients were investigated in this study, including patients with moderate (N = 90), severe (N = 50), and critical (N = 36) forms of COVID‐19. Also, the serum samples collected from healthy subjects before the COVID‐19 pandemic were used as controls (N = 176). The antinuclear antibodies (ANAs), antidouble‐stranded DNA (anti‐dsDNA), cytoplasmic‐anti neutrophil cytoplasmic antibody (c‐ANCA), perinuclear ANCA (p‐ANCA), antiphospholipid antibodies (aPLs), and anticyclic citrullinated peptide (anti‐CCP) occurrence was evaluated using a solid‐phase enzyme‐linked immunosorbent assay (ELISA). Results The results showed that the occurrence of ANAs, anti‐dsDNA, anti‐CCP, c‐ANCA, and p‐ANCA was significantly higher in the COVID‐19 patients compared to serum obtained from healthy subjects (p < .0001, p < .0001, p < .0001, p < .05, and p < .001, respectively). The positive number of anti‐CCP tests increased significantly in severe COVID‐19 compared to the moderate group (p < .01). Conclusion Our study further supports the development of autoantibodies related to systemic autoimmune rheumatologic diseases. To the best of our knowledge, this is the first study with a large sample size that reported the occurrence of anti‐CCP in a severe form of COVID‐19. Abstract Objectives The dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID‐19). This study was conducted to clarify the occurrence of autoantibodies (AABs) associated with systemic autoimmune rheumatic diseases (SARDs) in hospitalized patients with a moderate, severe, and critical form of COVID‐19. Methods The serum samples obtained from 176 hospitalized COVID‐19 patients were investigated in this study, including patients with moderate ( N = 90), severe ( N = 50), and critical ( N = 36) forms of COVID‐19. Also, the serum samples collected from healthy subjects before the COVID‐19 pandemic were used as controls ( N = 176). The antinuclear antibodies (ANAs), antidouble‐stranded DNA (anti‐dsDNA), cytoplasmic‐anti neutrophil cytoplasmic antibody (c‐ANCA), perinuclear ANCA (p‐ANCA), antiphospholipid antibodies (aPLs), and anticyclic citrullinated peptide (anti‐CCP) occurrence was evaluated using a solid‐phase enzyme‐linked immunosorbent assay (ELISA). Results The results showed that the occurrence of ANAs, anti‐dsDNA, anti‐CCP, c‐ANCA, and p‐ANCA was significantly higher in the COVID‐19 patients compared to serum obtained from healthy subjects ( p < .0001, p < .0001, p < .0001, p < .05, and p < .001, respectively). The positive number of anti‐CCP tests increased significantly in severe COVID‐19 compared to the moderate group ( p < .01). Conclusion Our study further supports the development of autoantibodies related to systemic autoimmune rheumatologic diseases. To the best of our knowledge, this is the first study with a large sample size that reported the occurrence of anti‐CCP in a severe form of COVID‐19. Objectives The dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID‐19). This study was conducted to clarify the occurrence of autoantibodies (AABs) associated with systemic autoimmune rheumatic diseases (SARDs) in hospitalized patients with a moderate, severe, and critical form of COVID‐19. Methods The serum samples obtained from 176 hospitalized COVID‐19 patients were investigated in this study, including patients with moderate (N = 90), severe (N = 50), and critical (N = 36) forms of COVID‐19. Also, the serum samples collected from healthy subjects before the COVID‐19 pandemic were used as controls (N = 176). The antinuclear antibodies (ANAs), antidouble‐stranded DNA (anti‐dsDNA), cytoplasmic‐anti neutrophil cytoplasmic antibody (c‐ANCA), perinuclear ANCA (p‐ANCA), antiphospholipid antibodies (aPLs), and anticyclic citrullinated peptide (anti‐CCP) occurrence was evaluated using a solid‐phase enzyme‐linked immunosorbent assay (ELISA). Results The results showed that the occurrence of ANAs, anti‐dsDNA, anti‐CCP, c‐ANCA, and p‐ANCA was significantly higher in the COVID‐19 patients compared to serum obtained from healthy subjects (p < .0001, p < .0001, p < .0001, p < .05, and p < .001, respectively). The positive number of anti‐CCP tests increased significantly in severe COVID‐19 compared to the moderate group (p < .01). Conclusion Our study further supports the development of autoantibodies related to systemic autoimmune rheumatologic diseases. To the best of our knowledge, this is the first study with a large sample size that reported the occurrence of anti‐CCP in a severe form of COVID‐19. The dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID-19). This study was conducted to clarify the occurrence of autoantibodies (AABs) associated with systemic autoimmune rheumatic diseases (SARDs) in hospitalized patients with a moderate, severe, and critical form of COVID-19.OBJECTIVESThe dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID-19). This study was conducted to clarify the occurrence of autoantibodies (AABs) associated with systemic autoimmune rheumatic diseases (SARDs) in hospitalized patients with a moderate, severe, and critical form of COVID-19.The serum samples obtained from 176 hospitalized COVID-19 patients were investigated in this study, including patients with moderate (N = 90), severe (N = 50), and critical (N = 36) forms of COVID-19. Also, the serum samples collected from healthy subjects before the COVID-19 pandemic were used as controls (N = 176). The antinuclear antibodies (ANAs), antidouble-stranded DNA (anti-dsDNA), cytoplasmic-anti neutrophil cytoplasmic antibody (c-ANCA), perinuclear ANCA (p-ANCA), antiphospholipid antibodies (aPLs), and anticyclic citrullinated peptide (anti-CCP) occurrence was evaluated using a solid-phase enzyme-linked immunosorbent assay (ELISA).METHODSThe serum samples obtained from 176 hospitalized COVID-19 patients were investigated in this study, including patients with moderate (N = 90), severe (N = 50), and critical (N = 36) forms of COVID-19. Also, the serum samples collected from healthy subjects before the COVID-19 pandemic were used as controls (N = 176). The antinuclear antibodies (ANAs), antidouble-stranded DNA (anti-dsDNA), cytoplasmic-anti neutrophil cytoplasmic antibody (c-ANCA), perinuclear ANCA (p-ANCA), antiphospholipid antibodies (aPLs), and anticyclic citrullinated peptide (anti-CCP) occurrence was evaluated using a solid-phase enzyme-linked immunosorbent assay (ELISA).The results showed that the occurrence of ANAs, anti-dsDNA, anti-CCP, c-ANCA, and p-ANCA was significantly higher in the COVID-19 patients compared to serum obtained from healthy subjects (p < .0001, p < .0001, p < .0001, p < .05, and p < .001, respectively). The positive number of anti-CCP tests increased significantly in severe COVID-19 compared to the moderate group (p < .01).RESULTSThe results showed that the occurrence of ANAs, anti-dsDNA, anti-CCP, c-ANCA, and p-ANCA was significantly higher in the COVID-19 patients compared to serum obtained from healthy subjects (p < .0001, p < .0001, p < .0001, p < .05, and p < .001, respectively). The positive number of anti-CCP tests increased significantly in severe COVID-19 compared to the moderate group (p < .01).Our study further supports the development of autoantibodies related to systemic autoimmune rheumatologic diseases. To the best of our knowledge, this is the first study with a large sample size that reported the occurrence of anti-CCP in a severe form of COVID-19.CONCLUSIONOur study further supports the development of autoantibodies related to systemic autoimmune rheumatologic diseases. To the best of our knowledge, this is the first study with a large sample size that reported the occurrence of anti-CCP in a severe form of COVID-19. |
Author | Roghani, Seyed Askar Rostampour, Rezvan Shamsi, Afsaneh Soufivand, Parviz Taghadosi, Mahdi Soleymani, Bijan Pournazari, Mehran Lotfi, Ramin Dastbaz, Mohammad Abdan, Zahra Zamanian, Mohammad Hossein |
AuthorAffiliation | 2 Clinical Research Development Center, Imam Reza Hospital Kermanshah University of Medical Sciences Kermanshah Iran 6 Department of Clinical Biochemistry, Medical School Kermanshah University of Medical Sciences Kermanshah Iran 3 Medical Biology Research Center, Health Technology Institute Kermanshah University of Medical Sciences Kermanshah Iran 4 Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Kurdistan Regional Blood Transfusion Center Sanandaj Iran 5 Clinical Research Development Center, Tohid Hospital Kurdistan University of Medical Sciences Sanandaj Iran 1 Immunology Department, Faculty of Medicine Kermanshah University of Medical Sciences Kermanshah Iran |
AuthorAffiliation_xml | – name: 4 Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Kurdistan Regional Blood Transfusion Center Sanandaj Iran – name: 5 Clinical Research Development Center, Tohid Hospital Kurdistan University of Medical Sciences Sanandaj Iran – name: 6 Department of Clinical Biochemistry, Medical School Kermanshah University of Medical Sciences Kermanshah Iran – name: 3 Medical Biology Research Center, Health Technology Institute Kermanshah University of Medical Sciences Kermanshah Iran – name: 2 Clinical Research Development Center, Imam Reza Hospital Kermanshah University of Medical Sciences Kermanshah Iran – name: 1 Immunology Department, Faculty of Medicine Kermanshah University of Medical Sciences Kermanshah Iran |
Author_xml | – sequence: 1 givenname: Seyed Askar surname: Roghani fullname: Roghani, Seyed Askar organization: Kermanshah University of Medical Sciences – sequence: 2 givenname: Mohammad surname: Dastbaz fullname: Dastbaz, Mohammad organization: Kermanshah University of Medical Sciences – sequence: 3 givenname: Ramin orcidid: 0000-0002-5421-5280 surname: Lotfi fullname: Lotfi, Ramin organization: Kurdistan University of Medical Sciences – sequence: 4 givenname: Afsaneh surname: Shamsi fullname: Shamsi, Afsaneh organization: Kermanshah University of Medical Sciences – sequence: 5 givenname: Zahra surname: Abdan fullname: Abdan, Zahra organization: Kermanshah University of Medical Sciences – sequence: 6 givenname: Rezvan surname: Rostampour fullname: Rostampour, Rezvan organization: Kermanshah University of Medical Sciences – sequence: 7 givenname: Bijan surname: Soleymani fullname: Soleymani, Bijan organization: Kermanshah University of Medical Sciences – sequence: 8 givenname: Mohammad Hossein surname: Zamanian fullname: Zamanian, Mohammad Hossein organization: Kermanshah University of Medical Sciences – sequence: 9 givenname: Parviz surname: Soufivand fullname: Soufivand, Parviz organization: Kermanshah University of Medical Sciences – sequence: 10 givenname: Mehran surname: Pournazari fullname: Pournazari, Mehran organization: Kermanshah University of Medical Sciences – sequence: 11 givenname: Mahdi orcidid: 0000-0002-3516-0130 surname: Taghadosi fullname: Taghadosi, Mahdi email: mtaghad@gmail.com organization: Kermanshah University of Medical Sciences |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38780036$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kstO3DAUhq2KqlDKoi9QReoGFgOOr8mqQqGXSEh0Qbu1bOdk8MgTp04Cml0foc_Ik-DMUASV6o0t-9Pn4-P_LdrrQgcIvc_xaY4xOXOuoac5keIVOiCY4wXjRO49W--jo2FYYYxzTCXFxRu0TwtZYEzFAYLrG8gauAUf-jV0YxbaTHejsxvrnc2sG-Pkvev0CE3WQz-6BrLjmbj__aeqvp9saROaTdYG78Od65bZkHwRsurqZ32RsLx8h1632g9w9Dgfoh9fPl9X3xaXV1_r6vxyYZnEYkGJ4SUjREiRCxDGEG6pFUaUheaSMc1ZQagBa4WljFsGwmIuLSuZtJQ09BDVO28T9Er10a113KigndpuhLhUOqbHeVCkZIyBNq0mJl0OJicaOAfZAC05xcn1aefqJ7OGxqbmRO1fSF-edO5GLcOtytMggshkOH40xPBrgmFUazdY8F53EKZBUcxLwiVmPKEf_0FXYYpd6lWixCwkskzUyY6yMQxDhPapmhyrOQxqDoOaw5DYD8_LfyL_fn0CznbAnfOw-b9J1fUF3SofAONVwAk |
Cites_doi | 10.1038/s41586-022-05273-0 10.1186/s13075-020-2121-6 10.1016/j.jtauto.2021.100091 10.1002/rmv.2316 10.1002/art.41425 10.1016/j.mehy.2008.12.040 10.1016/j.jaut.2023.103132 10.1111/cts.12805 10.26508/lsa.202101180 10.1007/s10067-023-06670-0 10.1002/rmv.2412 10.1016/j.jaut.2021.102682 10.1186/s12931-023-02650-9 10.1126/scitranslmed.abd3876 10.1586/1744666X.3.5.721 10.1136/annrheumdis-2021-219859 10.1002/art.20018 10.1007/s00296-021-04914-3 10.3389/fmed.2023.1201425 10.1038/s41586-021-03631-y 10.1136/annrheumdis-2015-208356 10.1016/j.cell.2022.01.014 10.1016/S0140-6736(20)30183-5 10.1038/s41572-020-0204-y 10.3389/fimmu.2018.00609 10.1016/j.intimp.2021.107806 10.1002/art.34380 10.1038/s41467-021-25509-3 10.1016/j.jaut.2019.06.006 10.3904/kjim.2013.28.1.25 10.1016/j.eclinm.2022.101783 10.1016/j.isci.2024.109573 10.1001/jama.2023.0157 10.1016/j.celrep.2020.108590 10.1136/ard.2005.041079 10.1002/art.40066 10.1172/JCI154886 10.1186/s13075-018-1752-3 10.3390/cells11182901 10.1016/j.ejr.2021.08.013 10.1056/NEJMoa2002032 10.1016/j.jtha.2023.02.033 |
ContentType | Journal Article |
Copyright | 2024 The Authors. published by John Wiley & Sons Ltd. 2024 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd. 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: 2024 The Authors. published by John Wiley & Sons Ltd. – notice: 2024 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd. – notice: 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | 24P WIN CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH K9. M0S PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1002/iid3.1276 |
DatabaseName | Open Access: Wiley-Blackwell Open Access Journals Wiley Online Library Free Content Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College Coronavirus Research Database ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) Coronavirus Research Database ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE Publicly Available Content Database CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
DocumentTitleAlternate | ROGHANI et al |
EISSN | 2050-4527 |
EndPage | n/a |
ExternalDocumentID | oai_doaj_org_article_29444eabfa2b470eb12ae55e7de39530 10_1002_iid3_1276 38780036 IID31276 |
Genre | article Journal Article |
GeographicLocations | Iran |
GeographicLocations_xml | – name: Iran |
GrantInformation_xml | – fundername: Deputy of Research and Technology of the Kermanshah University of Medical Sciences funderid: 4000648 – fundername: Deputy of Research and Technology of the Kermanshah University of Medical Sciences (KUMS) funderid: 4000648 – fundername: Deputy for Research and Technology, Kermanshah University of Medical Sciences funderid: 4000648 – fundername: Deputy of Research and Technology of the Kermanshah University of Medical Sciences (KUMS) grantid: 4000648 – fundername: Deputy for Research and Technology, Kermanshah University of Medical Sciences grantid: 4000648 – fundername: Deputy of Research and Technology of the Kermanshah University of Medical Sciences grantid: 4000648 |
GroupedDBID | 0R~ 1OC 24P 53G 5VS 7X7 8-1 8FI 8FJ AAHHS AAZKR ABDBF ABUWG ACCFJ ACXQS ADBBV ADKYN ADRAZ ADZMN ADZOD AEEZP AEQDE AFKRA AIWBW AJBDE ALAGY ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AOIJS AVUZU BAWUL BCNDV BENPR BPHCQ BVXVI CCPQU DIK EBS EJD ESX FYUFA GODZA GROUPED_DOAJ HMCUK HYE IAO IHR INH KQ8 M48 M~E O9- OK1 OVD PIMPY PQQKQ PROAC RPM TEORI UKHRP WIN CGR CUY CVF ECM EIF ITC NPM AAYXX CITATION 3V. 7XB 8FK AZQEC COVID DWQXO K9. PQEST PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c4706-32b5942267616e6bb25c3c6b698a5744a54823becc6c345c4e6c057c4947c32d3 |
IEDL.DBID | RPM |
ISSN | 2050-4527 |
IngestDate | Tue Oct 22 15:11:33 EDT 2024 Tue Sep 17 21:28:29 EDT 2024 Tue Aug 06 16:33:04 EDT 2024 Thu Oct 10 19:12:26 EDT 2024 Thu Sep 26 16:52:15 EDT 2024 Wed Oct 23 10:06:20 EDT 2024 Sat Aug 24 00:58:56 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | autoantibodies (AABs) COVID‐19 autoimmunity SARS‐CoV‐2 anti‐CCP |
Language | English |
License | Attribution 2024 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4706-32b5942267616e6bb25c3c6b698a5744a54823becc6c345c4e6c057c4947c32d3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-3516-0130 0000-0002-5421-5280 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11112627/ |
PMID | 38780036 |
PQID | 3061112279 |
PQPubID | 2034588 |
PageCount | 8 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_29444eabfa2b470eb12ae55e7de39530 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11112627 proquest_miscellaneous_3059257045 proquest_journals_3061112279 crossref_primary_10_1002_iid3_1276 pubmed_primary_38780036 wiley_primary_10_1002_iid3_1276_IID31276 |
PublicationCentury | 2000 |
PublicationDate | May 2024 |
PublicationDateYYYYMMDD | 2024-05-01 |
PublicationDate_xml | – month: 05 year: 2024 text: May 2024 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Bognor Regis – name: Hoboken |
PublicationTitle | Immunity, Inflammation and Disease |
PublicationTitleAlternate | Immun Inflamm Dis |
PublicationYear | 2024 |
Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc Wiley |
Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc – name: Wiley |
References | 2023; 10 2021; 4 2013; 28 2023; 56 2020; 382 2017; 69 2019; 105 2016; 75 2024; 142 2020; 13 2020; 12 2023; 329 2021; 122 2022; 44 2018; 20 2022; 611 2023; 61 2023; 42 2023; 21 2018; 9 2020; 6 2004; 50 2021; 98 2022; 185 2021; 12 2021; 34 2006; 65 2009; 72 2020; 395 2020; 72 2021; 131 2022; 32 2021; 595 2020; 22 2007; 3 2022; 33 2022; 11 2024; 25 2021; 41 2024; 27 2012; 64 2021; 80 e_1_2_11_10_1 e_1_2_11_32_1 e_1_2_11_31_1 e_1_2_11_30_1 e_1_2_11_36_1 e_1_2_11_14_1 e_1_2_11_13_1 e_1_2_11_35_1 e_1_2_11_12_1 e_1_2_11_34_1 e_1_2_11_11_1 e_1_2_11_33_1 e_1_2_11_7_1 e_1_2_11_29_1 e_1_2_11_6_1 e_1_2_11_28_1 e_1_2_11_5_1 Son K (e_1_2_11_21_1) 2023; 61 e_1_2_11_27_1 e_1_2_11_4_1 e_1_2_11_26_1 e_1_2_11_3_1 e_1_2_11_2_1 e_1_2_11_44_1 e_1_2_11_20_1 e_1_2_11_45_1 e_1_2_11_25_1 e_1_2_11_40_1 e_1_2_11_24_1 e_1_2_11_41_1 e_1_2_11_9_1 e_1_2_11_23_1 e_1_2_11_42_1 e_1_2_11_8_1 e_1_2_11_22_1 e_1_2_11_43_1 e_1_2_11_18_1 e_1_2_11_17_1 e_1_2_11_16_1 e_1_2_11_15_1 e_1_2_11_37_1 e_1_2_11_38_1 e_1_2_11_39_1 e_1_2_11_19_1 |
References_xml | – volume: 20 start-page: 264 issue: 1 year: 2018 article-title: The presence of anti‐nuclear antibodies alone is associated with changes in B cell activation and T follicular helper cells similar to those in systemic autoimmune rheumatic disease publication-title: Arthritis Res Ther – volume: 122 year: 2021 article-title: Unique autoantibody prevalence in long‐term recovered SARS‐CoV‐2‐infected individuals publication-title: J Autoimmun – volume: 33 issue: 2 year: 2022 article-title: Partners in crime: autoantibodies complicit in COVID‐19 pathogenesis publication-title: Rev Med Virol – volume: 142 year: 2024 article-title: Novel and unique rheumatoid factors cross‐react with viral epitopes in COVID‐19 publication-title: J Autoimmun – volume: 75 start-page: 1866 issue: 10 year: 2016 end-page: 1875 article-title: Single cell cloning and recombinant monoclonal antibodies generation from RA synovial B cells reveal frequent targeting of citrullinated histones of NETs publication-title: Ann Rheum Dis – volume: 42 start-page: 2905 issue: 10 year: 2023 end-page: 2914 article-title: Incident autoimmune diseases in association with SARS‐CoV‐2 infection: a matched cohort study publication-title: Clin Rheumatol – volume: 185 start-page: 881 issue: 5 year: 2022 end-page: 895.e20e820 article-title: Multiple early factors anticipate post‐acute COVID‐19 sequelae publication-title: Cell – volume: 25 start-page: 48 issue: 1 year: 2024 article-title: What is the actual relationship between neutrophil extracellular traps and COVID‐19 severity? A longitudinal study publication-title: Respir Res – volume: 4 year: 2021 article-title: Latent rheumatic, thyroid and phospholipid autoimmunity in hospitalized patients with COVID‐19 publication-title: J Transl Autoimmun – volume: 12 issue: 570 year: 2020 article-title: Prothrombotic autoantibodies in serum from patients hospitalized with COVID‐19 publication-title: Sci Transl Med – volume: 21 start-page: 2569 issue: 9 year: 2023 end-page: 2584 article-title: NETosis induction reflects COVID‐19 severity and long COVID: insights from a 2‐center patient cohort study in Israel publication-title: J Thromb Haemost – volume: 105 year: 2019 article-title: Cellular aging over 13 years associated with incident antinuclear antibody positivity in the Baltimore longitudinal study of aging publication-title: J Autoimmun – volume: 32 issue: 4 year: 2022 article-title: Complement inhibition: a possible therapeutic approach in the fight against Covid‐19 publication-title: Rev Med Virol – volume: 41 start-page: 1523 issue: 8 year: 2021 end-page: 1529 article-title: ANCA‐associated vasculitis after COVID‐19 publication-title: Rheumatol Int – volume: 72 start-page: 732 issue: 6 year: 2009 end-page: 735 article-title: Porphyromonas gingivalis may play an important role in the pathogenesis of periodontitis‐associated rheumatoid arthritis publication-title: Med Hypotheses – volume: 56 year: 2023 article-title: Risk of autoimmune diseases in patients with COVID‐19: a retrospective cohort study publication-title: EClinicalMedicine – volume: 69 start-page: 1165 issue: 6 year: 2017 end-page: 1175 article-title: Anti‐citrullinated protein antibodies are associated with neutrophil extracellular traps in the sputum in relatives of rheumatoid arthritis patients publication-title: Arthritis Rheumatol – volume: 22 start-page: 27 issue: 1 year: 2020 article-title: Association between periodontitis and anti‐citrullinated protein antibodies in rheumatoid arthritis patients: a cross‐sectional study publication-title: Arthritis Res Ther – volume: 3 start-page: 721 issue: 5 year: 2007 end-page: 738 article-title: Clinical implication of autoantibodies in patients with systemic rheumatic diseases publication-title: Expert Rev Clin Immunol – volume: 329 start-page: 701 year: 2023 article-title: Long COVID linked with unemployment in new analysis publication-title: JAMA – volume: 6 start-page: 71 issue: 1 year: 2020 article-title: ANCA‐associated vasculitis publication-title: Nat Rev Dis Primers – volume: 72 start-page: 1998 issue: 12 year: 2020 end-page: 2004 article-title: Antiphospholipid antibodies in critically ill patients with COVID‐19 publication-title: Arthritis Rheumatol – volume: 27 year: 2024 article-title: Association of vascular netosis with COVID‐19 severity in asymptomatic and symptomatic patients publication-title: iScience – volume: 12 start-page: 5417 issue: 1 year: 2021 article-title: New‐onset IgG autoantibodies in hospitalized patients with COVID‐19 publication-title: Nat Commun – volume: 9 year: 2018 article-title: Autoantibodies in autoimmune liver disease‐clinical and diagnostic relevance publication-title: Front Immunol – volume: 611 start-page: 139 issue: 7934 year: 2022 end-page: 147 article-title: Dysregulated naive B cells and de novo autoreactivity in severe COVID‐19 publication-title: Nature – volume: 4 issue: 11 year: 2021 article-title: Autoimmune anti‐DNA and anti‐phosphatidylserine antibodies predict development of severe COVID‐19 publication-title: Life Sci Alliance – volume: 395 start-page: 497 issue: 10223 year: 2020 end-page: 506 article-title: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China publication-title: Lancet – volume: 44 start-page: 145 issue: 2 year: 2022 end-page: 149 article-title: Systemic lupus erythematosus after coronavirus disease‐2019 (COVID‐19) infection: case‐based review publication-title: Egypt Rheumatol – volume: 61 issue: 1 year: 2023 article-title: Circulating anti‐nuclear autoantibodies in COVID‐19 survivors predict long COVID symptoms publication-title: Eur Respir J – volume: 50 start-page: 380 issue: 2 year: 2004 end-page: 386 article-title: Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors publication-title: Arthritis Rheum – volume: 382 start-page: 1708 issue: 18 year: 2020 end-page: 1720 article-title: Clinical characteristics of coronavirus disease 2019 in China publication-title: N Engl J Med – volume: 28 start-page: 25 issue: 1 year: 2013 end-page: 28 article-title: Anti‐citrullinated protein antibodies in rheumatoid arthritis: a bridge between genetic predisposition and autoimmunity publication-title: Korean J Intern Med – volume: 595 start-page: 283 issue: 7866 year: 2021 end-page: 288 article-title: Diverse functional autoantibodies in patients with COVID‐19 publication-title: Nature – volume: 11 start-page: 2901 issue: 18 year: 2022 article-title: Dysregulated neutrophil phenotype and function in hospitalised non‐ICU COVID‐19 pneumonia publication-title: Cells – volume: 65 start-page: 366 issue: 3 year: 2006 end-page: 371 article-title: Smoking is a risk factor for anti‐CCP antibodies only in rheumatoid arthritis patients who carry HLA‐DRB1 shared epitope alleles publication-title: Ann Rheum Dis – volume: 80 start-page: 1096 issue: 8 year: 2021 end-page: 1098 article-title: Onset of rheumatoid arthritis after COVID‐19: coincidence or connected? publication-title: Ann Rheum Dis – volume: 64 start-page: 2319 issue: 7 year: 2012 end-page: 2327 article-title: Prevalence and sociodemographic correlates of antinuclear antibodies in the United States publication-title: Arthritis Rheum – volume: 131 issue: 24 year: 2021 article-title: The intersection of COVID‐19 and autoimmunity publication-title: J Clin Invest – volume: 34 issue: 1 year: 2021 article-title: Cell‐type‐specific immune dysregulation in severely ill COVID‐19 patients publication-title: Cell Rep – volume: 10 year: 2023 article-title: Brief report: can COVID‐19 infection trigger rheumatoid arthritis‐associated autoimmunity in individuals at risk for the disease? A nested cohort study publication-title: Front Med – volume: 98 year: 2021 article-title: Advanced glycation end products (AGEs) and its receptor, RAGE, modulate age‐dependent COVID‐19 morbidity and mortality. A review and hypothesis publication-title: Int Immunopharmacol – volume: 13 start-page: 1077 issue: 6 year: 2020 end-page: 1086 article-title: Clinical and autoimmune characteristics of severe and critical cases of COVID‐19 publication-title: Clin Transl Sci – ident: e_1_2_11_8_1 doi: 10.1038/s41586-022-05273-0 – ident: e_1_2_11_35_1 doi: 10.1186/s13075-020-2121-6 – ident: e_1_2_11_9_1 doi: 10.1016/j.jtauto.2021.100091 – ident: e_1_2_11_7_1 doi: 10.1002/rmv.2316 – ident: e_1_2_11_31_1 doi: 10.1002/art.41425 – ident: e_1_2_11_36_1 doi: 10.1016/j.mehy.2008.12.040 – ident: e_1_2_11_14_1 doi: 10.1016/j.jaut.2023.103132 – ident: e_1_2_11_18_1 doi: 10.1111/cts.12805 – ident: e_1_2_11_26_1 doi: 10.26508/lsa.202101180 – ident: e_1_2_11_39_1 doi: 10.1007/s10067-023-06670-0 – ident: e_1_2_11_4_1 doi: 10.1002/rmv.2412 – ident: e_1_2_11_32_1 doi: 10.1016/j.jaut.2021.102682 – ident: e_1_2_11_43_1 doi: 10.1186/s12931-023-02650-9 – ident: e_1_2_11_12_1 doi: 10.1126/scitranslmed.abd3876 – ident: e_1_2_11_2_1 doi: 10.1586/1744666X.3.5.721 – ident: e_1_2_11_37_1 doi: 10.1136/annrheumdis-2021-219859 – ident: e_1_2_11_15_1 doi: 10.1002/art.20018 – ident: e_1_2_11_29_1 doi: 10.1007/s00296-021-04914-3 – volume: 61 issue: 1 year: 2023 ident: e_1_2_11_21_1 article-title: Circulating anti‐nuclear autoantibodies in COVID‐19 survivors predict long COVID symptoms publication-title: Eur Respir J contributor: fullname: Son K – ident: e_1_2_11_40_1 doi: 10.3389/fmed.2023.1201425 – ident: e_1_2_11_11_1 doi: 10.1038/s41586-021-03631-y – ident: e_1_2_11_42_1 doi: 10.1136/annrheumdis-2015-208356 – ident: e_1_2_11_13_1 doi: 10.1016/j.cell.2022.01.014 – ident: e_1_2_11_5_1 doi: 10.1016/S0140-6736(20)30183-5 – ident: e_1_2_11_28_1 doi: 10.1038/s41572-020-0204-y – ident: e_1_2_11_17_1 doi: 10.3389/fimmu.2018.00609 – ident: e_1_2_11_22_1 doi: 10.1016/j.intimp.2021.107806 – ident: e_1_2_11_25_1 doi: 10.1002/art.34380 – ident: e_1_2_11_10_1 doi: 10.1038/s41467-021-25509-3 – ident: e_1_2_11_23_1 doi: 10.1016/j.jaut.2019.06.006 – ident: e_1_2_11_34_1 doi: 10.3904/kjim.2013.28.1.25 – ident: e_1_2_11_38_1 doi: 10.1016/j.eclinm.2022.101783 – ident: e_1_2_11_45_1 doi: 10.1016/j.isci.2024.109573 – ident: e_1_2_11_20_1 doi: 10.1001/jama.2023.0157 – ident: e_1_2_11_24_1 doi: 10.1016/j.celrep.2020.108590 – ident: e_1_2_11_33_1 doi: 10.1136/ard.2005.041079 – ident: e_1_2_11_41_1 doi: 10.1002/art.40066 – ident: e_1_2_11_19_1 doi: 10.1172/JCI154886 – ident: e_1_2_11_16_1 doi: 10.1186/s13075-018-1752-3 – ident: e_1_2_11_30_1 doi: 10.3390/cells11182901 – ident: e_1_2_11_3_1 doi: 10.1002/art.20018 – ident: e_1_2_11_27_1 doi: 10.1016/j.ejr.2021.08.013 – ident: e_1_2_11_6_1 doi: 10.1056/NEJMoa2002032 – ident: e_1_2_11_44_1 doi: 10.1016/j.jtha.2023.02.033 |
SSID | ssj0001037308 |
Score | 2.3084266 |
Snippet | Objectives
The dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID‐19). This study was conducted to clarify... The dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID-19). This study was conducted to clarify the... Abstract Objectives The dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID‐19). This study was conducted to... ObjectivesThe dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID-19). This study was conducted to clarify... Abstract Objectives The dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID‐19). This study was conducted to... |
SourceID | doaj pubmedcentral proquest crossref pubmed wiley |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
StartPage | e1276 |
SubjectTerms | Adult Aged Anti-Citrullinated Protein Antibodies - blood Anti-Citrullinated Protein Antibodies - immunology Antibodies Antibodies, Antinuclear - blood Antibodies, Antinuclear - immunology anti‐CCP autoantibodies (AABs) Autoantibodies - blood Autoantibodies - immunology Autoimmune diseases Autoimmune Diseases - blood Autoimmune Diseases - immunology autoimmunity Coronaviruses Correlation analysis COVID-19 COVID-19 - blood COVID-19 - immunology Female Humans Immunoglobulins Lupus Male Middle Aged Neutrophils Original Patients Peptides Rheumatic diseases Rheumatic Diseases - blood Rheumatic Diseases - immunology Rheumatoid arthritis SARS-CoV-2 - immunology SARS‐CoV‐2 Sea level Severity of Illness Index |
SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LixQxEA6yIHgR37auEsXDemh3OqmkO0edddkRfBxc2VvIExuke_GBzM2f4G_0l1jVmRlnUPHibegUTeb7Kl2V7spXjD2aJR_AB1Gb2KoaTAO1yS7UXYBZEN6kRtMB55ev9MkpvDhTZ1utvqgmrMgDF-AOhQGA5Hx2wkOLt26ES0qlNiZplCy79UZtbaamtyszia7braWEZuKw76N80gjSFtkKQJNO_5-Sy99rJLdz1yn4HF9hl1dZI39aZnuVXUjDNXax9JFcXmcJyebxV_kPHzNHxPqwDB_6wAOdrCDtbcwrIz-nOpaY-AFZ_Pj2fT5_83iy9mNc8ox-MX7FeMYxZKaPic9fv1scoVljbrDT4-dv5yf1qn9CHRApXUvhlaGTsq1udNLeCxVk0F6bzqkWwOFuRUgiUQcJKkDSAdO3AAbaIEWUN9neMA7pNuNJZwz1jYqxM5AxqTNOq5xB5eg6HKjYwzWo9rzIZNgiiCwsIW8J-Yo9I7g3BqRsPV1Avu2Kb_svviu2vybLrpbbJ4v7HnxmkxhixR5shnGh0NcPN6TxC9koQy37QFXsVuF2MxPZtR0p81Ss22F9Z6q7I0P_fhLjppAjtGgrdjA5yN__vl0sjiT9uPM_cLjLLgnMr0rt5T7bQ0dK9zA_-uzvT0vhJzBjDvU priority: 102 providerName: Directory of Open Access Journals – databaseName: Coronavirus Research Database dbid: COVID link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB7BVkhceFMCBRnEoRyyTfxKfEKwpeoi8ThQ1FsUPwIRKFn6EFp-PTN57HZ5HbhFsQ925hvPF3v8DcDTJFgnreOx8ZmKpUllbKrSxbmTiePWhFTTBec3b_XhkXx9rI6HDbfTIa1yXBO7hdq3jvbI95DaoluS3t3zxbeYqkbR6epQQuMybIkc_3QmsDV793G-v95lSQRCOB8lhRK-V9deTFNOGiMXAlGn1_8nkvl7ruRFDtsFoYPrUIzD73NPvkzPz-zU_fhF2fH_53cDrg38lL3oAXUTLoXmFlzpK1Yub0OJsGJ-nWjE2oqhbWq3dF9rxxzd4SCVb2Swni0oY8YHtks94tns_bOur239klWIv_Y7xk2GoTmcBNZ90Tg1d-Do4NWH2WE8VGmIncwocY5bZeg-bqZTHbS1XDnhtNUmL1UmZYn_RFwQVLQTUjkZtEOS6KSRmRPci7swadom3AMWdIWEIlXe50ZWSB1NqVVVSVX5MseGCJ6MJisWvRhH0csu84LsWpBdI3hJxlx1IP3s7kV78qkY3LHgRkoZSluV3OIsMGDxMigVMh-EUSKJYGe0UjE49WmxNlEEj1fN6I50xlI2oT2nPspQYUCpItjukbMaiciznPR_Isg3MLUx1M2Wpv7cSX5TYOOaZxHsdvD7-_SL-Xxf0MP9f0_hAVzlyM_63M0dmCA8wkPkV2f20eBEPwGWgia4 priority: 102 providerName: ProQuest – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Nb9QwELVKERIXxHdTCjKIQzmkJPbYjg8IwZaqi1TgwKLeovgjEKlKyhYEe-Mn8Bv5Jcwk2aUrisQtiidSMvOceU7Gbxh7nEXnwXmR2mBUCjaH1NaVTwsPmRfOxlzTBuejN_pwBq-P1fEGW_bYHB14duHSjvpJzeYne98_L57jhH82Cog-bZog93Jh9CV2WYAEAvrRyPL7Ty2ZRBz3vekylaWghFlqDJ2_ei0z9QL-F7HOv4snz5PaPisdXGfXRjrJXwzxv8E2YnuTXRkaTC5usYgo4OFPXRDvao6ubPzCnzSee9pyQaLcSDgDP6UClxD5Lln8-vFzMnn3pLd2XVjwGgHTfcNExzGXxnnkk7cfpvtoltvbbHbw6v3kMB0bK6QeDNW6CacsbaE1OtdROyeUl147bYtKGYAKlzFCUnS1l6A8RO2R13mwYLwUQd5hm23Xxi3Go66RA-QqhMJCjWzPVlrVNag6VAUOJOzR0qnl6aCfUQ5KyaIkz5fk-YS9JHevDEjyuj_RzT-W4wwqhQWAWLm6Eg6fAnOMqKJS0YQorZJZwnaWwSqXMCpxQYQvc1JJTNjD1TDOIPotUrWx-0o2ylIvP1AJuzvEdnUnsjAFSfYkrFiL-tqtro-0zadepZtykdDCJGy3B8i_H7-cTvclHWz_v-k9dlUgvRpKL3fYJsIl3kd69MU96MH_GwbqDJI priority: 102 providerName: Scholars Portal – databaseName: Open Access: Wiley-Blackwell Open Access Journals dbid: 24P link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB6VIiQuiDeBggziUA6hiZ-xOMGWqosE9EBRb5FfKZFQUrUgtDd-Ar-RX8JMsptlBUjcongi2fPwfHbGnwGeFskH6QPPbTQql7aUuW1cyKsgi8C9TaWmA85v3-nDY_nmRJ1swYvVWZiRH2LacKPIGOZrCnDnL_bWpKFtG8Xzkht9CS4jrKnIpbk8Wm-wFAK9d7iRrlBFLhU3K2ahgu9NX2_ko4G2_29Y88-Syd-h7JCLDq7DtSWIZC9Hq9-ArdTdhCvjtZKLW5DQ9iyuq4FY3zBUYBsW4XMbWKCDFkTFjTAzsjMqa4mJ7ZLEz-8_ZrOjZ4O07-OCNegm_TdMbwwzaDpPbPb-43wfxUp7G44PXn-YHebL6xTyIA1VuHGvLB2cNbrUSXvPVRBBe20rp4yUDhcvXJBNdRBSBZl0QDQXpJUmCB7FHdju-i7dA5Z0g5m_VDFWVjaI8azTqmmkaqKrsCGDJyul1mcja0Y98iPzmjRfk-YzeEXqngSI6Hp40Z-f1su4qbmVUibnG8c9jgIzC3dJqWRiElaJIoOdlbHqZfRd1LgMwimcuBEzeDw1Y9zQzxDXpf4ryShLN_hJlcHd0bZTT0RlKiLqyaDasPpGVzdbuvbTwM1NGYhrbjLYHRzk38Ov5_N9QQ_3_1_0AVzlCKrGgssd2EZ3SQ8RFH3xjwbn_wU8kAfj priority: 102 providerName: Wiley-Blackwell |
Title | The development of anticyclic citrullinated peptide (anti‐CCP) antibody following severe COVID‐19 |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fiid3.1276 https://www.ncbi.nlm.nih.gov/pubmed/38780036 https://www.proquest.com/docview/3061112279 https://www.proquest.com/docview/3059257045/abstract/ https://pubmed.ncbi.nlm.nih.gov/PMC11112627 https://doaj.org/article/29444eabfa2b470eb12ae55e7de39530 |
Volume | 12 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEB41RUhcEG8MJVoQh3JwYu_Te6RpqwYpJUIU5WZ512uw1NpRAaHc-An8Rn4Js-s4JAIuXGzLO5J356GZWc98C_AyccZyY2msSyVirlMe66qwcWZ5YqnRLpW-wXl2Ls8u-JuFWOyB7HthQtG-NfWoubwaNfWnUFu5vLLjvk5sPJ9NvJlTiUn7AAaKsa0cPeysJAzVNuthhBI6ruuSjVLqcUW2nE_A6P9bYPlnfeR23Bocz-kduL2OGMnrbmZ3Yc819-Bmd4bk6j44FDQpf5f-kLYiyK3aruxlbYn1XRUedxtjypIsfQ1L6cihp_j5_cdkMn8VqE1brkiFOtF-Q19G0F26a0cmbz9Mj5Es1Q_g4vTk_eQsXp-dEFuufDkbNUL7LlklU-mkMVRYZqWROiuE4rzATIUyL0BpGReWO2kxdLNcc2UZLdlD2G_axj0G4mSFbj4VZZlpXmFApwspqoqLqiwyHIjgRc_UfNlBZOQdGDLNPedzz_kIjjy7NwQe1Tq8aK8_5mvZ5lRzzl1hqoIaXAW6EVo4IZwqHdOCJREc9MLK16b2Ocecx6sDVTqC55thNBL_56NoXPvV0wjtj-vjIoJHnWw3M2GZyjwqTwTZjtR3pro7gnoZgLh7PYzgMCjIv5efT6fHzD88-f-vPIVbFCOqrtryAPZRfdwzjIi-mCEMKJ_jVS3UEG4cnZzP3-E9KMkw7DLgdcazYTCUXxhKFGE |
link.rule.ids | 230,315,733,786,790,870,891,2115,2236,11589,12083,21416,24346,27955,27956,31752,31753,33777,33778,38549,43343,43838,43928,46085,46509,50847,50956,53825,53827,74100,74657,74767 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB7BVgguvAuBAgZxKIdsN34lPiHYUu1CWzi0qDcrfgRWoM3Sh9Dy65lJsrstrwO3KPbBznzj-WKPvwF4PojOS-d5akKuUmkymZqq9Gnh5cBzZ2Km6YLz3r4eHcq3R-qo23A76dIqF2tis1CH2tMe-RZSW3RL0rt7OfuWUtUoOl3tSmhchjUMrLzowdrw_cfx9mqXZSAQwsVCUmjAtyaTIPoZJ42Rc4Go0ev_E8n8PVfyPIdtgtDODbCL4be5J1_6Z6eu73_8ouz4__O7Cdc7fspetYC6BZfi9DZcaStWzu9AibBiYZVoxOqKoW0mfu6_TjzzdIeDVL6RwQY2o4yZENkm9UiHww8vmr6uDnNWIf7q7xg3GYbmeBxZ80XTzNyFw503B8NR2lVpSL3MKXGOO2XoPm6uMx21c1x54bXTpihVLmWJ_0RcEFS0F1J5GbVHkuilkbkXPIh16E3rabwPLOoKCUWmQiiMrJA6mlKrqpKqCmWBDQk8W5jMzloxDtvKLnNLdrVk1wRekzGXHUg_u3lRH3-ynTtabqSUsXRVyR3OAgMWL6NSMQ9RGCUGCWwsrGQ7pz6xKxMl8HTZjO5IZyzlNNZn1EcZKgwoVQL3WuQsRyKKvCD9nwSKC5i6MNSLLdPJ50bymwIb1zxPYLOB39-nb8fjbUEPD_49hSdwdXSwt2t3x_vvHsI1jlytzePcgB5CJT5CrnXqHncO9RN8pymf |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELZgEYgL4k1gAYM4LIfQxM_4hKCl2vJY9sCi3iy_ApFQU3ZBqP-emSRtt-Jxi-I52PPwfInH3xDyrEg-CB9YbqKWuTClyE3tQl4FUQTmTSoVXnD-cKQOT8TbuZwP9U9nQ1nlek_sNurYBvxHPgJoC2GJfHejeiiLOJ5MXy6_59hBCk9ah3YaF8klyJIFtnHQc73931JwcOZqTS5UsFHTRP6iZMg2ci4ldcz9f4Obf1ZNnkezXTqaXifXBhxJX_WGv0EupMVNcrnvLLm6RRyYn8ZtQRBtawo6bMIqfGsCDXjXAtm4AWlGusTKlpjoAUrk4_Hx807Wt3FFa_CT9hfkNwopNJ0mOv74eTbJS3ObnEzffBof5kM3hTwIjQVuzEuD92a1KlVS3jMZeFBemcpJLYSDbxfG0aQqcCGDSCoAmAvCCB04i_wO2Vu0i3SP0KRqSPyljLEyogaIZ5ySdS1kHV0FAxl5ulaoXfakGbanR2YWtW5R6xl5jareCCDPdfeiPf1ih7CxzAghkvO1Yx5WAYmFuSRl0jFxI3mRkf21oewQfGd26yoZebIZhrDBsxC3SO1PlJEGG_gJmZG7vV03M-GVrpCnJyPVjsV3pro7smi-dtTcmICYYjojB51z_Hv5djabcHy4__8lPCZXwM_t-9nRuwfkKgNI1Zdb7pM98JT0ECDRD_-o8_XfVFIJhA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+development+of+anticyclic+citrullinated+peptide+%28anti%E2%80%90CCP%29+antibody+following+severe+COVID%E2%80%9019&rft.jtitle=Immunity%2C+Inflammation+and+Disease&rft.au=Roghani%2C+Seyed+Askar&rft.au=Dastbaz%2C+Mohammad&rft.au=Lotfi%2C+Ramin&rft.au=Shamsi%2C+Afsaneh&rft.date=2024-05-01&rft.issn=2050-4527&rft.eissn=2050-4527&rft.volume=12&rft.issue=5&rft.epage=n%2Fa&rft_id=info:doi/10.1002%2Fiid3.1276&rft.externalDBID=10.1002%252Fiid3.1276&rft.externalDocID=IID31276 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2050-4527&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2050-4527&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2050-4527&client=summon |